JP2005516946A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516946A5
JP2005516946A5 JP2003554189A JP2003554189A JP2005516946A5 JP 2005516946 A5 JP2005516946 A5 JP 2005516946A5 JP 2003554189 A JP2003554189 A JP 2003554189A JP 2003554189 A JP2003554189 A JP 2003554189A JP 2005516946 A5 JP2005516946 A5 JP 2005516946A5
Authority
JP
Japan
Prior art keywords
present
tegaserod
granulation
formulations
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003554189A
Other languages
English (en)
Japanese (ja)
Other versions
JP4718776B2 (ja
JP2005516946A (ja
Filing date
Publication date
Priority claimed from EP01403339A external-priority patent/EP1321142A1/en
Application filed filed Critical
Publication of JP2005516946A publication Critical patent/JP2005516946A/ja
Publication of JP2005516946A5 publication Critical patent/JP2005516946A5/ja
Application granted granted Critical
Publication of JP4718776B2 publication Critical patent/JP4718776B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003554189A 2001-12-21 2002-12-20 5ht4部分アゴニスト医薬組成物 Expired - Fee Related JP4718776B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod
EP01403339.3 2001-12-21
PCT/EP2002/014674 WO2003053432A1 (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Publications (3)

Publication Number Publication Date
JP2005516946A JP2005516946A (ja) 2005-06-09
JP2005516946A5 true JP2005516946A5 (pt) 2006-01-19
JP4718776B2 JP4718776B2 (ja) 2011-07-06

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003554189A Expired - Fee Related JP4718776B2 (ja) 2001-12-21 2002-12-20 5ht4部分アゴニスト医薬組成物

Country Status (31)

Country Link
US (2) US20050106236A1 (pt)
EP (2) EP1321142A1 (pt)
JP (1) JP4718776B2 (pt)
KR (1) KR100980144B1 (pt)
CN (1) CN100464749C (pt)
AR (1) AR037937A1 (pt)
AT (1) ATE320807T1 (pt)
AU (1) AU2002361198B2 (pt)
BR (1) BR0215148A (pt)
CA (1) CA2470668C (pt)
CO (1) CO5640102A2 (pt)
CY (1) CY1105559T1 (pt)
DE (1) DE60210139T2 (pt)
DK (1) DK1458377T3 (pt)
EC (1) ECSP105163A (pt)
EG (1) EG24194A (pt)
ES (1) ES2258171T3 (pt)
HU (1) HU226589B1 (pt)
IL (2) IL162451A0 (pt)
MX (1) MXPA04006157A (pt)
MY (1) MY139546A (pt)
NO (1) NO20042779L (pt)
NZ (1) NZ533585A (pt)
PE (1) PE20030872A1 (pt)
PL (1) PL369509A1 (pt)
PT (1) PT1458377E (pt)
RU (1) RU2322978C2 (pt)
SI (1) SI1458377T1 (pt)
TW (1) TWI260221B (pt)
WO (1) WO2003053432A1 (pt)
ZA (1) ZA200404467B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141236A0 (en) * 1998-08-21 2002-03-10 Novartis Ag New oral formulations for 5-ht4 agonists or antagonists
SG192300A1 (en) 2003-01-28 2013-08-30 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2003222439A1 (en) * 2003-03-25 2004-10-18 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
WO2004104577A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
PE20050253A1 (es) * 2003-07-24 2005-06-03 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
DK1663182T4 (da) 2003-09-12 2020-02-17 Amgen Inc Hurtigt opløsende formulering af cinacalcet HCI
JP2007514000A (ja) * 2003-12-16 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド テガセロッド塩基及びその塩の多形現象形
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010078449A2 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN104902930A (zh) 2012-08-21 2015-09-09 阿德利克斯公司 在治疗与液体潴留或盐分过载相关的疾病和胃肠道疾病中用于抑制nhe-介导的反向转运的化合物和方法
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
HUE044550T2 (hu) 2013-04-12 2019-11-28 Ardelyx Inc NHE-3 megkötõ vegyületek és foszfát transzport gátlási módszerek
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
EA036204B1 (ru) * 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス, インコーポレイテッド Nhe媒介性アンチポートの阻害薬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd 1−アザビシクロ[3.3.0]オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
IL141236A0 (en) * 1998-08-21 2002-03-10 Novartis Ag New oral formulations for 5-ht4 agonists or antagonists
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
ES2435816T3 (es) * 1999-08-03 2013-12-23 Icos Corporation Formulación farmacéutica que comprende una Beta-carbolina y su uso para el tratamiento de la disfunción sexual

Similar Documents

Publication Publication Date Title
JP2005516946A5 (pt)
JP2002532112A5 (pt)
AU2002348983A1 (en) Heat activated durable styling compositions comprising saccharide type compounds and film forming agents
JP2003503454A5 (pt)
NO20041452L (no) 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer.
CA2463947A1 (en) Montelukast granule formulation
NO20053115D0 (no) Fremgangsmate for fremstilling av 2'-forgrenede nukleosider.
EA200400928A1 (ru) Диспергируемая во рту фармацевтическая композиция агомелатина
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
NO20024293D0 (no) Flekkfjernende tyggegummi og konfektblandinger, og fremgangsmåter for fremstilling av de samme
NO20052058D0 (no) Behandling av influensa.
DK1545230T3 (da) Belagt tyggegummi
NO20042410L (no) Sammensetning som omfatter angiopoietinliknende protein 3, ANGPTL3 og fremgangsmate til anvendelse av samme
ID30225A (id) Tablet matriks yang memungkinkan pelepasan yang diperlama dari gliklazida setelah pemberian secara oral
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
AP2004003154A0 (en) Novel perindopril salt and pharmaceutical compositions containing same.
RS49723B (sr) Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
SI1539114T1 (sl) Filmska obloga za tablete in kaplete
IS7413A (is) Nýjar 1,2,3,-setnar indólísín afleiður, hindrar af FGFS, aðferð við framleiðslu á þeim og lyfjafræðilegar samsetningar sem innihalda þau
IS6378A (is) Efnasambönd og samsetningar gegn dvergveirum, notkun þeirra til lyfjagerðar og efni til að framleiða þau
IS6956A (is) Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
JP2005509503A5 (pt)
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
HRP20080521T3 (en) Orodispersible pharmaceutical composition of an antithrombotic compound
DE50309337D1 (de) Calcium enthaltende süssigkeit